LexaGene Files Three Additional US Patents Covering Technology
BEVERLY, Mass. – July 17, 2019 – LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has filed additional patents to protect the proprietary science and designs of the LX2™ technology.
Three US patents have been recently filed, adding to the LexaGene intellectual property portfolio. The patent applications provide continuing and additional coverage to the technology of the unique sample prep DNA extraction method, the data and image processing algorithms and the fast microfluidic PCR functions of the instrument and system. This intellectual property advancement plus existing IP are continuing to provide LexaGene with a state-of-the-art, powerful and competitive low-cost platform for genetic testing.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “Protecting our technology is critical for building value in the Company. These patent applications further defend our LX technology as being the first sample-to-answer microfluidic genetic analyzer that utilizes disposable cartridges and bulk fluid reservoirs for rapid and cost-efficient PCR that can screen for many genetic targets at once.”
To be added to the LexaGene email distribution list, please subscribe on the Company website here.
About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.